11/06/2018
WPS Oncology Related LCD Updates
November 2018
November 2018 Local Coverage Determination (LCD)/Coverage Article Updates
The following is a summary of the Local Coverage Determination (LCD) and Coverage Article updates made by WPS GHA for November 2018. Additional details about these updates are available in the
full article on our website.
Please note: These changes will not be reflected in the LCDs and coverage articles until November 1, 2018.
New Policies/Articles - There are no new policies/articles for October 2018
Retired Policies/Articles
- MolDX: clonoSEQ® Assay for Assessment of Minimal Residual Disease (MRD) in Patients with Specific Lymphoid Malignancies - Effective November 1, 2018
- MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Advanced Primary Periotneal, Fallopian Tube and Ovarian Cancer - Effective November 1, 2018
- MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Colorectal Cancer - Effective November 1, 2018
- MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Melanoma - Effective November 1, 2018
- MolDX: NSCLC, Comprehensive Genomic Profile Testing - Effective November 1, 2018
Revised Policies/Articles
- MolDX: Afirma™ Assay by Veracyte Update - Effective November 1, 2018
- MolDX: Decipher® Prostate Cancer Classifier Assay - Effective November 1, 2018
- MolDX: Molecular Diagnostic Tests (MDT) - Effective October 1, 2018